Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.64 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RAD52 | P43351 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.63 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120849 | 0.88 | FTO (0.68) | MEN1KMT2AKDM4EMAPTFTO | |
| SCHEMBL3853314 | 0.86 | MEN1 (0.69) | MEN1KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL5107206 | 0.85 | FTO (0.64) | MEN1KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL4100436 | 0.84 | FTO (0.60) | MEN1KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL2023426 | 0.84 | FTO (0.63) | MEN1KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL1901643 | 0.84 | FTO (0.72) | MEN1KMT2AKDM4EMAPTCYP1A2 | |
| SCHEMBL3856490 | 0.82 | CA12 (0.76) | MEN1KMT2AKDM4EMAPTFTO | |
| SCHEMBL12660567 | 0.82 | FTO (0.74) | MEN1KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL8984675 | 0.82 | FTO (0.61) | MEN1KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL3853199 | 0.82 | CA12 (0.70) | MEN1KMT2AKDM4EMAPTFTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947839-B2 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947839-B2 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080221147-A1 | Method of inhibiting neurotrophin-receptor binding | ROSS GREGORY M | 2008-09-11 | — | — | US | disclosed |
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | CREDIA JAPAN CO., LTD. (JP) | 2008-06-12 | — | — | US | disclosed |
| US-7282575-B2 | Functional peptide nucleic acid monomer and process for producing the same | CREDIA JAPAN CO., LTD. (JP) | 2007-10-16 | — | — | US | disclosed |
| US-7282575-B2 | Functional peptide nucleic acid monomer and process for producing the same | CREDIA JAPAN CO., LTD. (JP) | 2007-10-16 | — | — | US | disclosed |
| WO-2007064345-A9 | HETEROCYCLIC-SUBSTITUTED BIS-1,8 NAPHTHALIMIDE COMPOUNDS, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE | GENENTECH INC (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1743886-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-17 | — | — | EP | disclosed |
| US-20060063793-A1 | Method of inhibiting neurotrophin-receptor binding | ROSS GREGORY M | 2006-03-23 | — | — | US | disclosed |
| US-20030203923-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-10-30 | — | — | US | disclosed |
| US-6492380-B1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-12-10 | — | — | US | disclosed |
| EP-1185515-A1 | METHOD OF INHIBITING NEUROTROPHIN-RECEPTOR BINDING | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000069828-A1 | METHOD OF INHIBITING NEUROTROPHIN-RECEPTOR BINDING | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063793-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | MEN1 3489/4885KMT2A 3466/4885KDM4E 2834/4885 |
| US-20030203923-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | MEN1 3799/4885KMT2A 3385/4885KDM4E 2289/4885 |
| US-20080221147-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | MEN1 3489/4885KMT2A 3466/4885KDM4E 2834/4885 |
| US-20070134243-A1 | Antibody drug conjugates and methods | BOD1L1, MKI67, CCNI | MEN1 1674/4885KMT2A 1301/4885KDM4E 2365/4885 |
| US-20080138817-A1 | Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same | NSUN3, RNGTT, NSUN2 | MEN1 3066/4885KMT2A 2806/4885KDM4E 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.